OBOlivier Boisvert

Olivier Boisvert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olivier Boisvert has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Agathe Fayolle

    Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, Quebec J1H 5N4, Canada

    1 shared publication
  • Marie-Édith Nepveu-Traversy

    Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, Quebec J1H 5N4, Canada

    1 shared publication
  • Michel Grandbois

    Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, Quebec J1H 5N4, Canada

    1 shared publication
  • Philippe Sarret

    Université de Sherbrooke

    1 shared publication
  • Pierre Lavigne

    Department of Biochemistry and Functional Genomics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, Quebec J1H 5N4, Canada

    1 shared publication
  • Pierre-Luc Boudreault

    Université de Sherbrooke

    1 shared publication

Latest Publications

  • Open Access

    Structure-Guided Design of Proteomimetics Targeting the SARS-CoV-2 S-RBD/hACE2 Interface

    by Sára Ferková, Agathe Fayolle, Olivier Boisvert, Ulrike Froehlich, Marie-Édith Nepveu-Traversy, Pierre Lavigne, Michel Grandbois, Philippe Sarret, Pierre-Luc Boudreault

    The SARS-CoV-2 Spike receptor-binding domain (S-RBD)/hACE2 interaction represents a challenging protein-protein interaction (PPI) target due to its large, shallow binding interface. Here, in silico alanine mutagenesis guided the structure-based design of constrained peptidomimetics that reproduce key hACE2 recognition elements. α1-helix-derived mimetics (Glu23-Ser44) were stabilized using peptide stapling strategies, while antiparallel β-sheet mimetics (Thr347-Leu359) were generated through head-to-tail macrocyclization incorporating a d-Pro/l-Pro motif. Covalent linkage of these two secondary structure mimetics yielded proteomimetic 28, designed to preserve the spatial organization of the hACE2 binding interface. Compound 28 selectively binds SARS-CoV-2 S-RBD and disrupts the S-RBD/hACE2 interaction in biophysical and cellular assays, inhibiting pseudovirus entry (IC50 of 6.6 μM). Importantly, 28 displays high stability in lung epithelial models (t1/2 > 24 h) and low epithelial permeability (Papp = 2.03 × 10-8 cm·s-1), supporting its potential for intranasal antiviral delivery. These findings establish a proof-of-concept for proteomimetics as promising inhibitors of challenging PPIs.